- Home
- KGEI vs PLX Comparison
KGEI vs PLX Comparison
Compare KGEI & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- PLX
- Stock Information
- Founded
- KGEI 2008
- PLX 1993
- Country
- KGEI United States
- PLX Israel
- Employees
- KGEI N/A
- PLX N/A
- Industry
- KGEI
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KGEI
- PLX Health Care
- Exchange
- KGEI Nasdaq
- PLX Nasdaq
- Market Cap
- KGEI 131.8M
- PLX 132.5M
- IPO Year
- KGEI N/A
- PLX 1998
- Fundamental
- Price
- KGEI $5.46
- PLX $1.73
- Analyst Decision
- KGEI
- PLX
- Analyst Count
- KGEI 0
- PLX 0
- Target Price
- KGEI N/A
- PLX N/A
- AVG Volume (30 Days)
- KGEI 30.9K
- PLX 404.5K
- Earning Date
- KGEI 11-12-2024
- PLX 11-14-2024
- Dividend Yield
- KGEI N/A
- PLX N/A
- EPS Growth
- KGEI 2.07
- PLX N/A
- EPS
- KGEI 0.48
- PLX N/A
- Revenue
- KGEI $54,654,000.00
- PLX $45,667,000.00
- Revenue This Year
- KGEI $15.80
- PLX N/A
- Revenue Next Year
- KGEI $12.21
- PLX $88.94
- P/E Ratio
- KGEI $11.06
- PLX N/A
- Revenue Growth
- KGEI 16.56
- PLX N/A
- 52 Week Low
- KGEI $2.84
- PLX $0.82
- 52 Week High
- KGEI $5.84
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- KGEI 79.45
- PLX 61.19
- Support Level
- KGEI $4.95
- PLX $1.57
- Resistance Level
- KGEI $5.84
- PLX $1.83
- Average True Range (ATR)
- KGEI 0.25
- PLX 0.07
- MACD
- KGEI 0.09
- PLX -0.02
- Stochastic Oscillator
- KGEI 78.16
- PLX 59.62
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. Its segments include the United States, Canada and Others. The company derives a majority of its revenue from the United States.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.